![](https://library.celltelligence.com/wp-content/uploads/2020/05/BMS-Earnings.png)
$0
BMS Highlights Ide-cel FDA Re-submission; Q2 2020 Earnings Call
On Thursday, August 6, BMS held their Q2 2020 results (press release / presentation). The company briefly discussed their CAR-T program, highlighting that the BLA for ide-cel in ≥4L RRMM has been re-submitted. In addition, management stated that they look forward to the November PDUFA date for liso-cel in ≥3L DLBCL. Below, Celltelligence provides thoughts on BMS’s two leading CAR-Ts, both of which have experienced delays to their FDA reviews.